S3866 HCPCS code: Genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (hcm) in an individual with a known hcm mutation in the family
S3866 is the HCPCS Level II code for genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (hcm) in an individual with a known hcm mutation in the family. Its Medicare coverage code is I (Not payable by Medicare): Medicare does not pay separately under this code; another code applies.
Code details
| Field | Value |
|---|---|
| Section | S codes — Temporary national codes (non-Medicare) |
| Coverage code | I — Not payable by Medicare |
| Pricing indicator | 00 — Not separately priced by Medicare |
| BETOS category | Z2 |
| Added | 2009-04-01 |
| Last action effective | 2009-04-01 |
What changed for S3866
- 2009-04-01: S3866 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code S3866?
S3866 is the HCPCS Level II code for genetic analysis for a specific gene mutation for hypertrophic cardiomyopathy (hcm) in an individual with a known hcm mutation in the family. Short descriptor: "Spec gene test hyp cardiomy".
Does Medicare cover S3866?
Coverage code I — Not payable by Medicare. Medicare does not pay separately under this code; another code applies.
Related S38 codes
- S3800 — Genetic testing for amyotrophic lateral sclerosis (als)
- S3840 — Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
- S3841 — Genetic testing for retinoblastoma
- S3842 — Genetic testing for von hippel-lindau disease
- S3844 — Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness
- S3845 — Genetic testing for alpha-thalassemia
- S3846 — Genetic testing for hemoglobin e beta-thalassemia
- S3849 — Genetic testing for niemann-pick disease
- S3850 — Genetic testing for sickle cell anemia
- S3852 — Dna analysis for apoe epsilon 4 allele for susceptibility to alzheimer's disease
- S3853 — Genetic testing for myotonic muscular dystrophy
- S3854 — Gene expression profiling panel for use in the management of breast cancer treatment
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under S3866
- Watch S3866 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for S3866
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.